California Poppy for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

California Poppy for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A dried flowering herb taken as tea, extract, or tablet for mild nervous tension and disturbed sleep, thought to strengthen the brain's calming signal. Benefits are modest, thinly supported: fewer night-time awakenings, slightly less daytime tension, no faster falling asleep. Drowsiness is the main drawback; in laboratory tests, alcohol-based extracts disturb liver drug-clearing enzymes. Product strength varies enormously between brands. (Full Review)

Protocol

Standardised monotherapy tablet
2 tablets nightly
Standardised tablet delivering 0.503 g of concentrated fresh-herb tincture per 1 g tablet, equivalent to 600 mg powdered herb, for four weeks
Best time of day
Evening only, 30–60 min before bed
Single evening dose for sleep; the anxiety trial split the daily amount into morning and evening doses
Traditional single-herb protocol
Review after two weeks
European regulators describe powdered dried aerial parts taken by mouth in adults for mild mental strain and as a sleep aid, with review if symptoms persist beyond two weeks
Time to effect
Sleep quality
4 weeks
Insomnia scores improved progressively over four weeks, with sleep duration gains appearing between week one and week four
Anxiety and tension
4 weeks
Anxiety is re-scored at two and four weeks; no measurable improvement by four weeks is the signal to stop
Sedative effect
Within a few hours
Present within a few hours of the first dose, which is why daytime dosing produces impairment rather than benefit

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Children and adolescents under 18 years
  • Known hypersensitivity to the poppy family (Papaveraceae)
  • Untreated moderate-to-severe obstructive sleep apnoea (above 15 events per hour)
  • Decompensated liver disease (Child-Pugh Class B or C)
  • Solid-organ transplant recipients on CYP3A4-dependent immunosuppressants
  • Drivers and machine operators dosing within 8 hours of duty
    •
Key Interactions
  • Benzodiazepines and Z-drugs (diazepam, lorazepam, zolpidem, zopiclone)
  • CYP3A4-dependent narrow-margin drugs (tacrolimus, ciclosporin, everolimus, midazolam)
  • CYP2C9 substrates (warfarin, phenytoin)
  • CYP2C19 substrates (clopidogrel, omeprazole, escitalopram)
  • CYP2D6 substrates (metoprolol, tamoxifen, codeine, many antidepressants)
  • Sedating antihistamines (diphenhydramine, doxylamine) and night-time analgesic combinations
  • Alcohol
  • Sedating supplements (valerian, hops, passionflower, kava, melatonin, magnesium, glycine, high-dose cannabidiol)
  • St John's wort
  • Surgery under general anaesthesia (withdrawn 1–2 weeks before)
    •

Risk & Side Effects

  • High:
  • Medium: Daytime drowsiness and reduced alertness
    •
  • Low: Gastrointestinal and mild psychological adverse events; inhibition of liver drug-metabolizing enzymes; unpredictable alkaloid dose between products; uncertain safety in pregnancy and breastfeeding
  • Speculative: Hypersensitivity in people sensitive to the poppy family; false-positive opiate result on urine screening

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) 10–26 U/L Hepatic reserve for clearing the alkaloids
Aspartate aminotransferase (AST) 10–26 U/L Confirms an ALT signal is hepatic rather than muscular
Gamma-glutamyl transferase (GGT) Under 20 U/L Most sensitive marker of hepatic stress and of alcohol intake that would compound sedation
International normalised ratio (INR) 2.0–3.0 while on warfarin Detects enzyme-mediated shifts in anticoagulation
Red blood cell magnesium 6.0–6.5 mg/dL Relevant when using the hawthorn and magnesium combination product
Trough level of a CYP3A4-dependent drug (tacrolimus, ciclosporin) No established target; tracked against the individual's own pre-herb trough and prescribed therapeutic window Detects the inhibition-then-induction pattern seen in vitro
Insomnia Severity Index Under 8 points Defines treatment success numerically

Cadence: Liver panel at baseline, plus the anticoagulation ratio or immunosuppressant trough where relevant. Any affected drug level rechecked 1–2 weeks after starting, stopping, or switching brands. Liver panel repeated only if use extends past three months, then every 6–12 months. Insomnia or anxiety re-scored at two and four weeks.

Qualitative Assessment

  • Residual morning sedation or impaired alertness on waking, which signals the dose is too high or taken too late
  • Number and duration of night-time awakenings, the endpoint most likely to move
  • Time to fall asleep, the endpoint least likely to move
  • Daytime alertness, concentration and driving confidence
  • Subjective tension and irritability during the day
  • Any new digestive discomfort, the commonest reported complaint
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.